MX2020003377A - Formulacion de tableta farmaceutica de dos capas. - Google Patents

Formulacion de tableta farmaceutica de dos capas.

Info

Publication number
MX2020003377A
MX2020003377A MX2020003377A MX2020003377A MX2020003377A MX 2020003377 A MX2020003377 A MX 2020003377A MX 2020003377 A MX2020003377 A MX 2020003377A MX 2020003377 A MX2020003377 A MX 2020003377A MX 2020003377 A MX2020003377 A MX 2020003377A
Authority
MX
Mexico
Prior art keywords
tablet formulation
pharmaceutical tablet
layer pharmaceutical
layer
novel
Prior art date
Application number
MX2020003377A
Other languages
English (en)
Inventor
Jonathan Louis Kaye
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of MX2020003377A publication Critical patent/MX2020003377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una nueva formulación de una tableta de dos capas, que comprende el inhibidor de transferencia de cadena de integrasa del VIH, dolutegravir, con el inhibidor de la transcriptasa inversa nucleósido, lamivudina.
MX2020003377A 2017-10-13 2018-10-08 Formulacion de tableta farmaceutica de dos capas. MX2020003377A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571863P 2017-10-13 2017-10-13
US201862634317P 2018-02-23 2018-02-23
PCT/US2018/054825 WO2019074826A2 (en) 2017-10-13 2018-10-08 FORMULATION OF BICOLET PHARMACEUTICAL TABLET

Publications (1)

Publication Number Publication Date
MX2020003377A true MX2020003377A (es) 2020-09-28

Family

ID=66101717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003377A MX2020003377A (es) 2017-10-13 2018-10-08 Formulacion de tableta farmaceutica de dos capas.

Country Status (18)

Country Link
US (1) US20200230141A1 (es)
EP (2) EP3694522B1 (es)
JP (2) JP7774958B2 (es)
KR (2) KR20200070246A (es)
CN (2) CN111246851A (es)
AU (1) AU2018347990B2 (es)
BR (1) BR112020006783A2 (es)
CA (1) CA3078624A1 (es)
CL (1) CL2020000959A1 (es)
ES (1) ES3056013T3 (es)
FI (1) FI3694522T3 (es)
IL (1) IL273704B2 (es)
MX (1) MX2020003377A (es)
PL (1) PL3694522T3 (es)
PT (1) PT3694522T (es)
TW (1) TWI841539B (es)
WO (1) WO2019074826A2 (es)
ZA (1) ZA202002263B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519290A (ja) * 2019-02-05 2022-03-22 ヴィーブ ヘルスケア カンパニー ドルテグラビル及びラミブジンでｈｉｖを治療する方法
WO2021116244A1 (en) * 2019-12-12 2021-06-17 Sandoz Ag Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs
CN111991558B (zh) * 2020-08-28 2022-08-09 安徽贝克生物制药有限公司 一种抗逆转录病毒药物组合物及其制备方法
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
US9713622B2 (en) * 2009-11-20 2017-07-25 Université Versailles Saint-Quentin-En-Yvelines Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
LT3494972T (lt) * 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
US20170189402A1 (en) * 2012-03-28 2017-07-06 Abbvie Inc. Solid dosage forms
AU2013336491B2 (en) * 2012-10-23 2018-08-02 Cipla Limited Pharmaceutical antiretroviral composition
IN2013MU01749A (es) 2013-05-15 2015-06-26 Cipla Ltd
WO2016016279A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用

Also Published As

Publication number Publication date
ZA202002263B (en) 2024-10-30
AU2018347990A1 (en) 2020-04-23
CA3078624A1 (en) 2019-04-18
KR20250004136A (ko) 2025-01-07
CL2020000959A1 (es) 2021-02-26
IL273704A (en) 2020-05-31
EP3694522B1 (en) 2025-11-26
BR112020006783A2 (pt) 2020-10-06
WO2019074826A2 (en) 2019-04-18
WO2019074826A3 (en) 2020-04-02
JP2020536931A (ja) 2020-12-17
IL273704B2 (en) 2024-06-01
CN117281788A (zh) 2023-12-26
AU2018347990B2 (en) 2021-09-09
EP4667003A2 (en) 2025-12-24
EP3694522A2 (en) 2020-08-19
IL273704B1 (en) 2024-02-01
EP3694522A4 (en) 2021-08-04
RU2020118376A3 (es) 2022-02-01
JP7774958B2 (ja) 2025-11-25
PL3694522T3 (pl) 2026-03-02
JP2025165977A (ja) 2025-11-05
US20200230141A1 (en) 2020-07-23
EP4667003A3 (en) 2026-02-25
TW201927290A (zh) 2019-07-16
CN111246851A (zh) 2020-06-05
FI3694522T3 (fi) 2026-02-05
ES3056013T3 (en) 2026-02-17
PT3694522T (pt) 2025-12-15
TWI841539B (zh) 2024-05-11
RU2020118376A (ru) 2021-11-15
KR20200070246A (ko) 2020-06-17

Similar Documents

Publication Publication Date Title
USD868269S1 (en) Finger splint
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
AU2018223054B2 (en) Asymmetric multilayer film for ostomy application
ZA202002263B (en) Bi-layer pharmaceutical tablet formulation
EP4072520C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CABOTEGRAVIR
NI201900052A (es) Formulaciones farmacéuticas
MA44720A (fr) Comprimés à désintégration orale
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP4037659C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE
EP4069214C0 (en) POLYPHOSPHAZENE-BASED DRUG CARRIERS
PL3965739T3 (pl) Postacie dawkowane będące tabletkami oleilofosfocholiny
MA56011A (fr) Formulation de comprimé vaginal
PT3357492T (pt) Comprimido com múltiplas camadas para a administração de magnésio
JP2020084867A5 (es)
JP2019058493A5 (es)
EP4027974C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING P-BORONOPHENYLALANINE
PL4034115T3 (pl) Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina
CL2019003833S1 (es) Horquilla.
AR113763A1 (es) Formulación farmacéutica de comprimidos bicapa
CL2023001908S1 (es) Tableta.
WO2017060666A8 (en) Layer pad
ES1254199Y (es) Identificador de medicamentos.
JP1694948S (ja) 錠剤
IT201700106078A1 (it) Composizione farmaceutica a base di cannabinoidi.
JP1694619S (ja) 錠剤